Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.

BMC Cancer · 2020 · PMC7670803 · PMID 33198652

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with moderate or massive ascites showed a trend toward favorable outcomes for PFS in the nab-PTX plus RAM group ( P for interaction = 0.051), whereas there was no obvious trend observed for OS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.